A Natural Human Retrovirus Efficiently Complements Vectors Based on Murine Leukemia Virus by Dong, Beihua et al.
A Natural Human Retrovirus Efficiently Complements
Vectors Based on Murine Leukemia Virus
Beihua Dong
1, Robert H. Silverman
1, Eugene S. Kandel
2¤*
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, 2Department of Molecular Genetics and Virology,
Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
Abstract
Background: Murine Leukemia Virus (MLV) is a rodent gammaretrovirus that serves as the backbone for common gene
delivery tools designed for experimental and therapeutic applications. Recently, an infectious gammaretrovirus designated
XMRV has been identified in prostate cancer patients. The similarity between the MLV and XMRV genomes suggests a
possibility that the two viruses may interact when present in the same cell.
Methodology/Principal Findings: We tested the ability of XMRV to complement replication-deficient MLV vectors upon co-
infection of cultured human cells. We observed that XMRV can facilitate the spread of these vectors from infected to
uninfected cells. This functional complementation occurred without any gross rearrangements in the vector structure, and
the co-infected cells produced as many as 10
4 infectious vector particles per milliliter of culture medium.
Conclusions/Significance: The possibility of encountering a helper virus when delivering MLV-based vectors to human cells
in vitro and in vivo needs to be considered to ensure the safety of such procedures.
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Introduction
Development of vectors based on murine leukemia virus was a
major step in the advent of experimental as well as therapeutic
retroviral transduction[1]. With appropriate pseudotyping, MLV-
based vectors could be used to transduce virtually any animal cell
type, including those of mammalian, non-mammalian vertebrate
and even invertebrate origin. Examples of the numerous
applications include gene expression, insertional mutagenesis,
marking of cells, as well as modeling the events of transcription
and reverse transcription. Although replication-competent virus is
occasionally used, most commonly the experiments are conducted
with replication-deficient vectors. To this end, all or most of the
protein-coding areas of the virus genome are removed and a
‘‘cargo’’ of interest is incorporated instead. The genomic transcript
encompassing such a modified virus genome could be packaged in
an infectious virion form if the missing protein functions are
provided in trans, either transiently or from pre-integrated
constructs in appropriately engineered packaging cells. While the
virion may infect naı ¨ve cells, resulting in integration of the provirus
in the DNA of the new host, the genes encoding the packaging
proteins normally will not be transferred. Consequently, no further
replication of the vector occurs and the virus will not spread
beyond the progeny of the originally infected cell. This condition is
heavily relied upon when the use of such vectors is considered.
The situation would radically change if the viral proteins are
expressed in the transduced cell, as might happen, for example,
when the same cells are inhabited by a replication-competent
MLV variant. This is a serious concern for the use of MLV in
murine cells, where closely related retroviruses are sometimes
found [2]. In addition, the proteins from related avian reticulo-
endotheliosis viruses (REV), such as spleen necrosis virus (SNV),
could enable replication of MLV-based vectors [3]. On the other
hand, the lack of reported natural replication-competent MLV
variants in human population would make spontaneous comple-
mentation of replication-deficient vectors improbable. This was
considered an additional safeguard for the use of these constructs,
since a vector that enters human population during gene therapy
or as a result of a laboratory accident is unlikely to spread.
Recently, a human retrovirus designated XMRV has been
found in prostatic tissue samples from human prostate cancer
patients [4], [5] and a closely-related virus has been found in at
least one cultured human cell line (unpublished observation).
XMRV was present in 8 (40%) of 20 patients homozygous for a
reduced activity variant of RNase L, and in just 1 (1.5%) of 66
patients that harbored at least one copy of the wild type allele.
XMRV displayed certain similarities with xenotropic strains of
MLV, including three highly variable regions in the Env protein
(SU or gp70) known to be important for species tropism, and was
classified as a gammaretrovirus [5]. We decided to investigate
whether the similarity between the two viruses may enable XMRV
to complement a replicative defect of MLV-based vectors.
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Cells were cultured at 37uC in a 5% CO2 atmosphere in RPMI
medium containing 10% FBS and supplemented with penicillin and
streptomycin. Infections were carried out using filtered supernatants
in the presence of polybrene as described elsewhere [6]. G418
selection was conducted at 0.5 mg/ml. The cells were fixed in
methanol and visualized by staining with methylene blue (2% in
methanol). DNA extraction was conducted using Blood and Cell
Culture DNA Midi Kit from Qiagen, Inc. Southern blotting with a
probe for the MLV packaging signal was described earlier [7]. The
GFP-specific probe corresponded to the Age I–Not I fragment of
pEGFP-N1fromClontech.PCR wasdone withtheearlierdescribed
MLV LTR-specific primers [8] and the primers within LNCE (sense
primer: 59-GGCCAGCAACTTATCTGTGT-39; anti-sense prim-
er: 59-AGCTTGAGCTCGAGATCTGA-39).
Results
In order to test the ability of XMRV to mobilize MLV-based
vectors we devised an experimental scheme (Figure 1A) that
utilized LNCE, a previously described MLV-based construct
(Figure 1B) [6], which carries the genes for neomycin resistance
and green fluorescent protein. DU145 human prostate carcinoma
cells were stably transduced with LNCE, and a population of
G418-resistant cells was obtained. As expected, this pool of cells,
designated DU145LNCE, was nearly uniformly positive for GFP
expression (data not shown). These cells were exposed to the
filtered supernatant of DU145XMRV (DU145 cells that were
previously infected with a replication-competent XMRV) and
cultured for additional week to allow a potential helper virus to
propagate. If XMRV could serve as a helper virus for LNCE, one
may expect doubly-infected cells to produce infectious LNCE
particles. To test this prediction, we collected the supernatant from
XMRV-infected DU145LNCE cells, filtered it and applied to
fresh DU145 cells. Two days later, the freshly infected cells were
subjected to G418 selection. We observed massive formation of
G418-resistant colonies, most of which showed detectable GFP
expression by fluorescent microscopy (data not shown). No G418-
resistant colonies were obtained in control experiment in which
fresh DU145 cells were exposed to DU145LNCE supernatant in
the absence of XMRV (e.g. Figure 2d). These observations suggest
that XMRV can act as a helper virus for MLV-based vectors.
Figure 1. XMRV facilitates the transfer of MLV-based LNCE to naı ¨ve cells. A. The scheme of the experimental approach. DU145LNCE and
DU145XMRV were generated by infecting DU145 cells with LNCE and XMRV respectively. The supernatant from DU145XMRV or fresh DU145 cells was
applied onto DU145LNCE cultures. The treated cells were cultivated for additional week, and the presence of infection LNCE particles in the
supernatant was tested by applying the latter to naı ¨ve DU145 cells (designated DU145XL or DU145CL respectively). The cells were selected in the
presence of G418. No DU145CL cells survived the selection. B. Structure of LNCE[6]. LTR-MLV long terminal repeat; psi-MLV packaging signal; neo-
neomycin resistance gene; CMV–cytomegalovirus promoter/enhancer region; GFP–the gene for enhanced green fluorescent protein. Positions of
hybridization probes (thick lines) and PCR products (dotted lines) are shown below and above the diagram respectively. The predicted sizes of the
PCR fragments and the distance between the two KpnI sites are indicated. C. Amplification of LNCE LTR from DU145XL cells. The expected product
was obtained from the DNA of the pooled G418-resistant cells (lane 1) and several individually expanded clones (lanes 2–4), but not the original
DU145 (lane 5). D. Amplification of an internal LNCE provirus fragment from DU145XL cells. The product was obtained from the DNA of DU145XL
(lane 1), but not the naı ¨ve DU145 (lane 2). E. Detection of transmission of LNCE in the presence of XMRV by Southern blotting. Hybridization with the
probe derived from the GFP fragment was performed on KpnI-digested DNA from DU145 (lane 1), DU145XMRV (lane 2), DU145LNCE (lane 3) and
DU145XL (lane 4).
doi:10.1371/journal.pone.0003144.g001
XMRV Rescues MLV-Based Vectors
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tation may be a recombination event, which would incorporate
the elements necessary for XMRV replication into LNCE.
However, co-expression of both marker genes in the newly
infected cells argues that the process does not require gross
rearrangements of LNCE. To further confirm the predicted
structure of LNCE provirus in the newly infected cells we
isolated DNA from the infected pool. Positive PCR signals were
obtained using LNCE-specific primers (Figure 1C, D). Sequenc-
ing of the PCR-amplified material revealed that the fragment
corresponding to the packaging signal of MLV is retained in the
newly formed proviruses (data not shown). Furthermore, we
analyzed KpnI-digested DNA from the infected cells by
Southern blotting with the probes generated from GFP
(Figure 1E) and MLV packaging signal (data not shown). The
same 4.3 kb fragment appears to hybridize with both probes, as
is expected for a full-length LNCE provirus. These observations
confirm that in the presence of XMRV, LNCE genomes could
be transferred to naı ¨ve cells without sustaining any major
structural rearrangements.
In order to investigate how efficiently LNCE is mobilized by
XMRV, we estimated the titer of LNCE that was produced by
XMRV-infected DU145LNCE cells. The titer could not be
accurately measured by a simple count of G418-resistant colonies:
in the presence of a helper virus there is a possibility for LNCE to
go through multiple rounds of replication, and thus more than
one colony could originate from a single initial particle. To
circumvent this problem, filtered supernatant conditioned by
XMRV-infected DU145LNCE cells has been serially diluted, and
the last dilution to contain the neo-transducing particles was
determined. The estimated virus titer was approximately 10
4
transducing particles per milliliter (Figure 2). This is comparable
to what has been reported for similar MLV-based vectors
produced in early-generation MLV-specific packaging cells. Of
note, much higher virus yields obtained by modern techniques
cannot be directly compared to our data since they are typically
obtained either from individually selected high-producing clones
or from cells harboring a high copy number of both the vector
and the packaging constructs. Overall, we concluded that the
ability of XMRV proteins to support propagation of replication-
deficient MLV is comparable to that of the native MLV-derived
factors.
Discussion
Our observations provide additional experimental evidence in
support of classifying XMRV as an MLV variant. Incorporation of
unrelated RNAs in retroviral particles is possible, but inefficient.
For example, SNV incorporates heterologous RNA at least 1000-
fold less efficient than the RNA with proper packaging signals
[9,10]. Similarly, MLV is very efficient in packaging related mouse
endogenous retroviruses, but not unrelated cellular RNAs [9].
Additional blocks at the level of reverse transcription and
integration may further impede stable transduction of naı ¨ve cells
with non-viral sequences, accounting for a nearly eight orders of
magnitude difference between the replication efficiencies of
constructs with or without specific retroviral cis-elements[10].
Various not mutually exclusive processes, such as aberrant splicing
[11], or recombination between the viral and cellular sequences at
the level of DNA[12], during transcription[13] and reverse
transcription[14], [15] have been discussed as potential contrib-
utors to this process. However, neither of these mechanisms could
explain the high frequency transduction of apparently intact
LNCE in our experiments. Structure-based interactions in the
absence of strong sequence homology have been alleged in cross-
packaging of REV and MLV retroviruses [16]. However, the
extended packaging signal of Moloney Murine Leukemia Virus,
an MLV variant that served as the backbone for LNCE, displays
about 70% homology with XMRV sequence. Therefore, the
sequence-based recognition remains the most likely explanation
for our observations.
The fact that a popular class of retroviral vector could readily
become infectious in the presence of natural human virus has to be
seriously considered whenever these constructs are being used,
especially in a clinical setting. The most obvious concern is the
possibility that a vector could accidentally encounter XMRV and
would spread in human populations. In the case of gene therapy,
the therapeutic construct might spread from the intended tissue
target throughout the organism or even to additional individuals.
An even more deleterious, albeit less probable, event might be an
accidental escape of an experimental vector that harbors an
oncogenic ‘‘cargo’’. Modern MLV-based vectors have undergone
extensive engineering to improve their performance in specialized
tasks [1]. For example, mutations in the long terminal repeats have
been used to improve expression, especially in embryonic cells[17].
Figure 2. Determination of the titer of infectious LNCE in the presence of XMRV. The supernatant from DU145LNCE cells exposed to the
medium from either DU145 (control medium) or DU145XMRV cells was applied in various dilutions to subconfluent cultures of naı ¨ve DU145 cells
grown in 6-well plates. The treated cells were selected for G418 resistance and the surviving colonies were visualized by methylene blue staining.
Neo-transducing particles were readily detectable in the supernatant of XMRV-exposed cells at 1,000-fold (panel A) and 10,000-fold (panel B), but not
100,000-fold (panel C) dilutions. The supernatant from DU145LNCE exposed to control medium was not toxic by itself (panel E), but it failed to
transduce the resistance marker even when used without dilution (panel D).
doi:10.1371/journal.pone.0003144.g002
XMRV Rescues MLV-Based Vectors
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recombination with natural viruses, potentially increasing patho-
genicity of the latter.
Another concern arises from the possibility to encounter
XMRV in the cultures of human cells, where the virus might
appear as the result of viremia of the original donor or due to
laboratory contamination during establishment or further propa-
gation of the cell lines. A pool of MLV-based constructs
introduced into such cells will likely evolve over time and may
spread to other cells, especially in co-culture experiments. In
addition, in some instances live attenuated vaccines could
potentially become contaminated with XMRV. Importantly, our
preliminary observations suggest the presence of an XMRV-like
retrovirus in a cultured cell line (unpublished observations).
It should be noted that a number of currently used vectors are
so-called ‘‘self-inactivating’’: after one round of replication their
LTRs lose the promoter function. Promoter-deficiency is known to
greatly diminish the risk of insertional mutagenesis [7], and it also
decreases the risk of a vector-derived RNA being packaged in a
virion in case the packaging proteins are introduced into the same
cell. Unfortunately, this safeguard is unlikely to be full-proof:
integration of the construct under the control of a cellular
promoter might re-create a transcript that incorporates the vector
genome, and RNAs with non-canonical placement of packaging
signal could still be packaged [18].
Additional work is required to estimate the likelihood of
XMRV-assisted propagation of MLV-based vectors in human
population. So far, XMRV has been identified only in a limited
number of humans, and the extent of its spread in human
populations is unknown. Moreover, little is known about its
tropism and the mode of infection. The association of XMRV
infection with reduced function of RNase L may indicate that the
virus could be sustained only in the individuals with decreased
anti-viral responses [4,5]. Moreover, co-packaging of XMRV and
MLV genomes is yet to be documented, as is the recombination
between the two viruses. Nevertheless, we believe that our
observations warrant additional caution for the use of MLV-
based vectors. In particular, they argue against the use of gene
therapy vectors with functional LTRs; in favor of vector designs
that minimize the likelihood of recombination with XMRV; and
in favor of testing model human cell lines for the presence of
MLV-complementing activity. In the meantime, it remains to be
seen whether the differences between MLV and XMRV are
enough to enable re-derivation of MLV-based vector systems that
would lose the ability to be complemented by XMRV.
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